Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C37H42N2O7 |
| Molecular Weight | 626.7386 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)COC5=NN(CC6=CC=CC=C6)C7=C5C=CC=C7
InChI
InChIKey=DYVIEGCPUPGXOH-HGGPGNIHSA-N
InChI=1S/C37H42N2O7/c1-35-16-14-25(40)18-24(35)12-13-26-28-15-17-37(44,36(28,2)19-30(41)33(26)35)31(42)21-45-32(43)22-46-34-27-10-6-7-11-29(27)39(38-34)20-23-8-4-3-5-9-23/h3-11,18,26,28,30,33,41,44H,12-17,19-22H2,1-2H3/t26-,28-,30-,33+,35-,36-,37-/m0/s1
Bendacort is an ester of glucocorticosteroid hydrocortisone and non-steroidal anti-inflammatory drug bendazac. In vivo studies demonstrated that bendacort has a wider spectrum of anti-inflammatory effects than bendazac or hydrocortisone alone: bendacort acts on responses with a necrotic evolution where tissue damage predominates, and in cases where the reaction of tissue defense predominates, as for example in the healing of wounds. Bendacort was marketed in Italy under tradename Versacort for the treatment of sensitive steroid dermatoses, contact eczema, dyshidrosis, insect bites.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
93288
Created by
admin on Mon Mar 31 19:52:43 GMT 2025 , Edited by admin on Mon Mar 31 19:52:43 GMT 2025
|
PRIMARY | |||
|
53716-43-1
Created by
admin on Mon Mar 31 19:52:43 GMT 2025 , Edited by admin on Mon Mar 31 19:52:43 GMT 2025
|
PRIMARY | |||
|
DTXSID00968474
Created by
admin on Mon Mar 31 19:52:43 GMT 2025 , Edited by admin on Mon Mar 31 19:52:43 GMT 2025
|
PRIMARY | |||
|
EF5DH3EFH5
Created by
admin on Mon Mar 31 19:52:43 GMT 2025 , Edited by admin on Mon Mar 31 19:52:43 GMT 2025
|
PRIMARY | |||
|
258-710-3
Created by
admin on Mon Mar 31 19:52:43 GMT 2025 , Edited by admin on Mon Mar 31 19:52:43 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD